New horizons for Alzheimer's disease: Potential disease-modifying anti-amyloid therapies

New horizons for Alzheimer's disease: Potential disease-modifying anti-amyloid therapies

Détails bibliographiques
Auteurs principaux:	Orgogozo, J, Golde, T, Wilcock, G
Format:	Conference item
Publié:	2007

Documents similaires

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
par: Randall J. Bateman, et autres
Publié: (2022-11-01)

Recent Alzheimer's disease research highlights.
par: Galasko, D, et autres
Publié: (2012)

Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
par: Yixiu Zhou, et autres
Publié: (2018-06-01)

Anti-amyloid therapies do not slow Alzheimer's disease progression
par: Markku Kurkinen
Publié: (2024-01-01)

Are we ready to use anti-amyloid therapy in Alzheimer's disease?
par: Sonia Maria Dozzi Brucki, et autres
Publié: (2022-08-01)

Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease.
par: Williams, S, et autres
Publié: (2005)

Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease
par: Williams, S, et autres
Publié: (2005)

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
par: Vijay K. Ramanan, et autres
Publié: (2023-06-01)

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
par: Christian Haass, et autres
Publié: (2022-07-01)

Non-immunoglobin in cerebrospinal fluid of patients with Alzheimer's disease and cerebral amyloid angiopathy.
par: Esiri, M, et autres
Publié: (1985)

Welcome to Alzheimer's research and therapy.
par: Donnelly, A, et autres
Publié: (2009)

The relationship between CAV-1 and cerebral amyloid angiopathy in Alzheimer's disease
par: Chalmers, K, et autres
Publié: (2004)

Anti-amyloid β hydrophobic peptides in Alzheimer’s disease: biomarkers and therapeutic potential
par: Carlos Gutierrez-Merino
Publié: (2025-02-01)

Disease-modifying treatments for Alzheimer's disease: a perspective based on experience with R-Flurbiprofen.
par: Wilcock, G
Publié: (2006)

Anti-amyloid agents for treating incipient Alzheimer’s disease: a new hope?
par: Julia C. Loureiro, et autres
Publié: (2022-06-01)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
par: V. S. D. Melo, et autres
Publié: (2023-03-01)

Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
par: Miners, J, et autres
Publié: (2006)

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
par: Maria Luisa Moro, et autres
Publié: (2018-01-01)

Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease.
par: van Helmond, Z, et autres
Publié: (2007)

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
par: Jeffrey Fessel
Publié: (2022-01-01)

Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer’s Disease in Japan
par: Kenichiro Sato, et autres
Publié: (2024-10-01)

Focused ultrasound therapy for Alzheimer’s disease: exploring the potential for targeted amyloid disaggregation
par: Kurt Scott, et autres
Publié: (2024-08-01)

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease
par: Charles G. Withington, et autres
Publié: (2022-03-01)

Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism.
par: Katzov, H, et autres
Publié: (2004)

Amyloid imaging in Alzheimer’s disease: a potential new era of personalized medicine?
par: Leuzy Antoine, et autres
Publié: (2014-03-01)

Advancements in Alzheimer's Disease Therapy: The Role of Anti-Amyloid Monoclonal Antibodies - A Literature Review
par: Agnieszka Skoczeń, et autres
Publié: (2025-03-01)

APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease.
par: Chalmers, K, et autres
Publié: (2004)

Disease-modifying trials in Alzheimer's disease: a European task force consensus.
par: Vellas, B, et autres
Publié: (2007)

Aluminium Binding to Modified Amyloid-β Peptides: Implications for Alzheimer’s Disease
par: Cosmin Stefan Mocanu, et autres
Publié: (2020-10-01)

Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
par: Jimin Kim, et autres
Publié: (2025-01-01)

Beyond amyloid: New approaches to Alzheimer's disease treatment
Publié: (2020-01-01)

Reduced neprilysin expression in Alzheimer's disease is associated with APOE E4 and cerebral amyloid angiopathy
par: Miners, J, et autres
Publié: (2006)

Alternatives to amyloid for Alzheimer's disease therapies—a symposium report
par: Cable, Jennifer, et autres
Publié: (2021)

Neurotrophins in Alzheimer's disease
par: Wilcock, G
Publié: (2002)

Treatment for Alzheimer's disease.
par: Wilcock, G
Publié: (2000)

Anti-amyloid immunotherapy in Alzheimer’s disease: The new dawn emerging from 179 clinical trials
par: Longmin Fan, et autres
Publié: (2024-10-01)

Therapeutic Potential of Direct Clearance of the Amyloid-β in Alzheimer’s Disease
par: Dong Eun Kim, et autres
Publié: (2020-02-01)

Amyloid, Crohn’s disease, and Alzheimer’s disease - are they linked?
par: Anna Duda-Madej, et autres
Publié: (2024-05-01)

Velnacrine for Alzheimer's disease.
par: Birks, J, et autres
Publié: (2004)

Mitochondrial β-amyloid in Alzheimer's disease.
par: Borger, E, et autres
Publié: (2011)